Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Inclusion Criteria: 1. Age, 18-75 years old. 2. Patients with newly histologically confirmed NPC. 3. WHO Type Ⅱ and Ⅲ. 4. Tumor staged as Ⅲ-ⅣA (according to the 8th AJCC edition). 5. No serious organ dysfunction of heart, lung, liver, kidney. 6. No distant metastasis. 7. Hematological examinations:WBC≥3.5×109/L, NEUT#≥1.5×109/L, PLT≥90×109/L, HB≥90g/L. 8. Normal liver function test：Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \<1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤1.5×ULN，creatinine clearance ≥60 ml/min. 9. Patients must be given written informed consent. Exclusion Criteria: 1. age \>75 years or \<18years. 2. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 3. History of previous radiotherapy and chemotherapy. 4. Known or suspected to be allergic to platinum and Nab-paclitaxel. 5. Pregnancy or lactation. 6. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial. 7. Peripheral sensory neuropathy\> grade 1. 8. Uncontrolled heart clinical symptoms or diseases.